Randomized comparative trial and cost analysis of 3-day antimicrobial regimens for treatment of acute cystitis in women

JAMA. 1995 Jan 4;273(1):41-5.

Abstract

Objective: To determine the efficacy, safety, and costs associated with four different 3-day regimens for the treatment of acute uncomplicated cystitis in women.

Design: A prospective randomized trial with a cost analysis.

Study population: Women with acute cystitis attending a student health center.

Interventions: Treatment with 3-day oral regimens of trimethoprim-sulfamethoxazole, 160 mg/800 mg twice daily, macrocrystalline nitrofurantoin, 100 mg four times daily, cefadroxil, 500 mg twice daily, or amoxicillin, 500 mg three times daily.

Results: Six weeks after treatment, 32 (82%) of 39 women treated with trimethoprim-sulfamethoxazole were cured compared with 22 (61%) of 36 treated with nitrofurantoin (P = .04 vs trimethoprim-sulfamethoxazole), 21 (66%) of 32 treated with cefadroxil (P = .11 vs trimethoprim-sulfamethoxazole), and 28 (67%) of 42 treated with amoxicillin (P = .11 vs trimethoprim-sulfamethoxazole). Persistence of significant bacteriuria was less common with trimethoprim-sulfamethoxazole (3%) and cefadroxil (0%) compared with nitrofurantoin (16%; P = .05 vs trimethoprim-sulfamethoxazole) and amoxicillin (14%; P = .11 vs trimethoprim-sulfamethoxazole). Persistence of bacteriuria was associated with amoxicillin-resistant strains in the amoxicillin group but nitrofurantoin-susceptible strains in the nitrofurantoin group. Trimethoprim-sulfamethoxazole was more successful in eradicating Escherichia coli from rectal cultures soon after therapy and from urethral and vaginal cultures at all follow-up visits compared with the other treatment regimens. Adverse effects were reported by 16 (35%) of 46 patients receiving trimethoprim-sulfamethoxazole, 18 (43%) of 42 receiving nitrofurantoin, 12 (30%) of 40 receiving cefadroxil, and 13 (25%) of 52 receiving amoxicillin. The mean costs per patient were less with trimethoprim-sulfamethoxazole ($114) and amoxicillin ($131) compared with nitrofurantoin ($155) and cefadroxil ($155).

Conclusions: A 3-day regimen of trimethoprim-sulfamethoxazole is more effective and less expensive than 3-day regimens of nitrofurantoin, cefadroxil, or amoxicillin for treatment of uncomplicated cystitis in women. The increased efficacy of trimethoprim-sulfamethoxazole is likely related to its antimicrobial effects against E coli in the rectum, urethra, and vagina.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • Acute Disease
  • Adult
  • Amoxicillin / economics
  • Amoxicillin / therapeutic use
  • Anti-Infective Agents / administration & dosage
  • Anti-Infective Agents / adverse effects
  • Anti-Infective Agents / economics*
  • Anti-Infective Agents / therapeutic use*
  • Cefadroxil / economics
  • Cefadroxil / therapeutic use
  • Confidence Intervals
  • Costs and Cost Analysis
  • Cystitis / drug therapy*
  • Cystitis / economics
  • Cystitis / microbiology
  • Drug Administration Schedule
  • Female
  • Humans
  • Nitrofurantoin / economics
  • Nitrofurantoin / therapeutic use
  • Ofloxacin / economics
  • Ofloxacin / therapeutic use
  • Prospective Studies
  • Rectum / microbiology
  • Treatment Outcome
  • Trimethoprim, Sulfamethoxazole Drug Combination / economics
  • Trimethoprim, Sulfamethoxazole Drug Combination / therapeutic use
  • Urethra / microbiology
  • Vagina / microbiology

Substances

  • Anti-Infective Agents
  • Cefadroxil
  • Amoxicillin
  • Trimethoprim, Sulfamethoxazole Drug Combination
  • Nitrofurantoin
  • Ofloxacin